FDA rejects Hengrui, Elevar PD-1 liver cancer combo a 3rd time
Fierce Pharma reports: FDA rejects Hengrui, Elevar PD-1 liver cancer combo a 3rd time.
Elevar Therapeutics
Private
Elevar Therapeutics is a private oncology-focused biopharmaceutical company developing and commercializing cancer therapies, including programs in liver cancer and other solid tumors.